Immersion Investment Views Strata Critical Medical (SRTA) as a “Babushka Doll” Soumya Eswaran Tue, August 11, 2026 at 3:44 PM GMT+2 3 min read SRTA Immersion Investment Partners, an investment management company, released its second-quarter 2025 investor letter. A copy of the letter can be downloaded here. Immersion Investment Partners returned 39.1% in the second quarter, surpassing the Russell 2000 Index's 21.5% gain.
The market started valuing their non-AI investments more rationally in the quarter, focusing on strong management, revenue growth, and improving cash flow. The firm capitalized on market selloffs due to macroeconomic factors unrelated to company fundamentals, increasing positions at lower prices, which led to gains in several holdings as they rebounded in the second quarter. In addition, please check the firm's top five holdings to know its best picks in 2026.
In its Q2 2026 investor letter, Immersion Investment Partners highlighted Strata Critical Medical, Inc. (NASDAQ:SRTA). Strata Critical Medical, Inc. (NASDAQ:SRTA) is a US-based company that provides time-critical logistics and medical services to the healthcare industry. On August 10, 2026, Strata Critical Medical, Inc. (NASDAQ:SRTA) closed at $5.94 per share, reflecting a market capitalization of $525.49 million.
Strata Critical Medical, Inc. (NASDAQ:SRTA) posted a one‑month return of 11.84%, while its shares gained 31.22% over the past 52 weeks. Immersion Investment Partners stated the following regarding Strata Critical Medical, Inc. (NASDAQ:SRTA) in its Q2 2026 investor letter: "Strata Critical Medical, Inc. (NASDAQ:SRTA) is a newer holding for the partnership, having been purchased in September 2025. The history surrounding the stock is intriguing to us because it's the abandoned remainco of an overhyped COVID-era SPAC.
Strata itself is a leading provider of organ transplant logistics and clinical services, but most investors have never heard of it. The business operated and grew in the shadows as a subsidiary of the former e-mobility company Blade, which came public via a SPAC in late 2020 to significant fanfare and bulge-bracket bank coverage from the likes of JP Morgan, Deutsche Bank, CitiGroup, and Credit Suisse. Like many 2020 SPACs, the Blade e-mobility business disappointed and the stock faltered, peaking at $20 in early 2021 and swiftly plunging to $2 by late 2023.
In August 2025, the company announced that it was selling its e-mobility, or 'Passenger,' business to Joby, would retain the organ logistics and services business and rebrand to Strata Critical Medical (ticker: SRTA). The transaction closed later that month for $76 million in Joby shares and a $35 million earnout. Most analysts who promoted the stock up until then abandoned the name.
Extract — continue reading at the source.
